Business & Regulation

From gene therapy to novel excipients to trends in leadership and more. Check out some of our most popular videos.

Within two years, pharma companies may be able to rely on technology to automatically create and cross-check entire regulatory submissions.

Stakeholders explain why the NIH’s move to cap indirect costs associated with research grants could damage medical innovation.

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

We speak with Sanofi’s Anju Bhalla about its appeal against NICE’s final draft guidance for Sarclisa.

Senate committee votes in favor of the nomination; full Senate vote will be next.

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

Here’s a roundup of ten of the most eye-catching deals so far in 2025.

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in healthcare systems.